Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): Results from a phase II prospective trial.
R. Rouzier
Honoraria - Roche
E. Lambaudie
No relevant relationships to disclose
J. Pierga
Consultant or Advisory Role - Roche
Research Funding - Roche
T. Petit
No relevant relationships to disclose
T. Delozier
No relevant relationships to disclose
J. Ferrero
No relevant relationships to disclose
M. Campone
No relevant relationships to disclose
J. Gligorov
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
F. Lerebours
No relevant relationships to disclose
H. Roche
No relevant relationships to disclose
D. Pau
Employment or Leadership Position - Roche
P. Viens
No relevant relationships to disclose
R. J. Salmon
No relevant relationships to disclose